BIOAFFINITY TECHNOLOGIES INC REPORTS Q1 2026 NET LOSS OF $3.6 MILLION, EQUIVALENT TO $0.81 PER SHARE
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 08 2026
0mins
Source: moomoo
- Financial Performance: BioAffinity Technologies reported a net loss of $3.6 million for the first quarter of 2026.
- Earnings Per Share: The company's earnings per share stood at $0.81.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BIAF?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BIAF
About BIAF
bioAffinity Technologies, Inc. is a biotechnology company focused on the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and broad-spectrum cancer treatments. It develops noninvasive diagnostics to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis developed by machine learning, a form of artificial intelligence (AI). The Company’s product, CyPath Lung, is a noninvasive test that has shown high sensitivity, specificity and accuracy for the detection of early-stage lung cancer. CyPath is marketed as a Laboratory Developed Test (LDT) by Precision Pathology Laboratory Services, a subsidiary of the Company. CyPath Lung uses flow cytometry technology to detect and analyze cell populations in a person’s sputum, or phlegm, to find characteristics indicative of lung cancer, including cancer and/or cancer-related cells that have shed from a lung tumor.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
bioAffinity Technologies Prices Public Offering for $3.2 Million
- Offering Details: bioAffinity Technologies is pricing 4,000,000 shares of common stock at $0.80 each, aiming for gross proceeds of $3.2 million, reflecting strong market confidence in its noninvasive lung cancer detection technology.
- Underwriter Role: WallachBeth Capital LLC acts as the sole placement agent for the offering, enhancing the company's capital market execution capabilities and providing professional support throughout the financing process.
- Transaction Timeline: The offering is expected to close on June 18, 2026, subject to customary closing conditions, providing the company with liquidity to support its research and market expansion efforts.
- Compliance Statement: The offering adheres to SEC registration requirements, ensuring all securities transactions comply with relevant laws, demonstrating the company's commitment to regulatory compliance and investor protection.
See More
bioAffinity Technologies Prices Public Offering Raising $3.2 Million
- Public Offering Details: bioAffinity Technologies announced a public offering of 4,000,000 shares at $0.80 each, expected to close on June 18, 2026, raising $3.2 million, indicating the company's active engagement in capital markets and financing capabilities.
- Use of Proceeds and Impact: The funds will support the further development of its non-invasive lung cancer detection product, CyPath® Lung, enhancing the company's competitiveness in early cancer diagnostics to meet the growing healthcare demand.
- CyPath® Lung Test Performance: Clinical trials of CyPath® Lung in high-risk patients demonstrated 92% sensitivity and 99% negative predictive value, indicating its effectiveness in early lung cancer detection and potentially reducing unnecessary invasive procedures for patients.
- Market Outlook and Strategy: Positioned for non-invasive early cancer diagnosis, bioAffinity Technologies is poised for significant growth in the coming years as demand for early detection increases, further solidifying its position in the biotechnology sector.
See More
CyPath®Lung Sales Surge Nearly 300% in April 2026
- Sales Surge: bioAffinity Technologies reported that unit sales of its CyPath® Lung diagnostic test increased nearly 300% in April 2026 compared to the same month in 2025, based on preliminary unaudited data, indicating strong physician adoption and exceeding internal projections.
- Addressing Clinical Needs: The rise in patients identified with indeterminate pulmonary nodules, partly due to increased low-dose CT screenings, highlights the diagnostic challenges faced by physicians, which CyPath® Lung's flow cytometry and AI technology aims to alleviate by providing actionable insights for early lung cancer detection.
- Focused Commercial Strategy: bioAffinity Technologies has prioritized CyPath® Lung as its core focus, driving growth through the expansion of ordering physician sites, enhanced peer-to-peer education among pulmonologists, and integration into clinical workflows, thereby improving lung cancer risk management.
- Future Expansion Plans: The company is advancing multiple initiatives to enhance the clinical impact of its proprietary technology platform, including a large-scale longitudinal clinical study and broader use of CyPath® Lung for monitoring lung cancer survivors, demonstrating its commitment to early cancer detection and market potential.
See More
bioAffinity Technologies Reports Q1 Financial Results
- Financial Performance: bioAffinity Technologies reported a Q1 GAAP EPS of -$0.81, indicating ongoing challenges in profitability and reflecting persistent financial pressure on the company.
- Revenue Decline: The company generated $1.35 million in revenue for the first quarter, a significant drop from $6.2 million in the same period last year, suggesting a potential weakening in market demand that could impact future growth prospects.
- Liquidity Concerns: As of March 31, 2026, cash and cash equivalents stood at $3.1 million, down from $6.4 million as of December 31, 2025, highlighting urgent issues in cash management and operational sustainability.
- Clinical Integration Efforts: bioAffinity Technologies is discussing the clinical integration of its CyPath lung product in pulmonary nodule assessment and early lung cancer diagnosis, which, despite poor financial results, may pave the way for future market opportunities.
See More
CyPath® Lung Diagnostic Sales Surge 146% Year-Over-Year
- Significant Sales Growth: In Q1 2026, CyPath® Lung diagnostic unit sales surged 146% year-over-year, reflecting rapid physician adoption and expanded clinical use, thereby enhancing the company's competitive edge in the non-invasive lung cancer detection market.
- Revenue Changes: CyPath® Lung testing revenue reached approximately $361,000, a 114% increase, while total revenue decreased by 27% to $1.4 million, primarily due to the discontinuation of unprofitable pathology services, allowing a focus on higher-margin CyPath® Lung testing.
- Clinical Trial Launch: The company initiated a large-scale longitudinal clinical trial, partially funded by the U.S. Department of Defense, expected to include up to 20 clinical sites, aimed at further validating CyPath® Lung's performance and establishing it as a standard of care in military and Veterans Administration medical centers.
- Strategic Investment and Market Expansion: bioAffinity Technologies plans to conduct a 40-patient collaborative study with Brooke Army Medical Center, utilizing its flow cytometry + AI technology to evaluate its platform's application in personalized therapy, further driving market acceptance of CyPath® Lung.
See More
BIOAFFINITY TECHNOLOGIES INC REPORTS 27% DROP IN TOTAL CONSOLIDATED REVENUE TO $1.4 MILLION FOR Q1 2026
- Revenue Decline: BioAffinity Technologies reported a 27% decrease in consolidated revenue, totaling $1.4 million in Q1 2026.
- Financial Performance: The significant drop in revenue indicates potential challenges for the company in maintaining financial stability and growth.
See More
bioAffinity Technologies Prices Public Offering for $3.2 Million
- Offering Details: bioAffinity Technologies is pricing 4,000,000 shares of common stock at $0.80 each, aiming for gross proceeds of $3.2 million, reflecting strong market confidence in its noninvasive lung cancer detection technology.
- Underwriter Role: WallachBeth Capital LLC acts as the sole placement agent for the offering, enhancing the company's capital market execution capabilities and providing professional support throughout the financing process.
- Transaction Timeline: The offering is expected to close on June 18, 2026, subject to customary closing conditions, providing the company with liquidity to support its research and market expansion efforts.
- Compliance Statement: The offering adheres to SEC registration requirements, ensuring all securities transactions comply with relevant laws, demonstrating the company's commitment to regulatory compliance and investor protection.
See More
bioAffinity Technologies Prices Public Offering Raising $3.2 Million
- Public Offering Details: bioAffinity Technologies announced a public offering of 4,000,000 shares at $0.80 each, expected to close on June 18, 2026, raising $3.2 million, indicating the company's active engagement in capital markets and financing capabilities.
- Use of Proceeds and Impact: The funds will support the further development of its non-invasive lung cancer detection product, CyPath® Lung, enhancing the company's competitiveness in early cancer diagnostics to meet the growing healthcare demand.
- CyPath® Lung Test Performance: Clinical trials of CyPath® Lung in high-risk patients demonstrated 92% sensitivity and 99% negative predictive value, indicating its effectiveness in early lung cancer detection and potentially reducing unnecessary invasive procedures for patients.
- Market Outlook and Strategy: Positioned for non-invasive early cancer diagnosis, bioAffinity Technologies is poised for significant growth in the coming years as demand for early detection increases, further solidifying its position in the biotechnology sector.
See More
CyPath®Lung Sales Surge Nearly 300% in April 2026
- Sales Surge: bioAffinity Technologies reported that unit sales of its CyPath® Lung diagnostic test increased nearly 300% in April 2026 compared to the same month in 2025, based on preliminary unaudited data, indicating strong physician adoption and exceeding internal projections.
- Addressing Clinical Needs: The rise in patients identified with indeterminate pulmonary nodules, partly due to increased low-dose CT screenings, highlights the diagnostic challenges faced by physicians, which CyPath® Lung's flow cytometry and AI technology aims to alleviate by providing actionable insights for early lung cancer detection.
- Focused Commercial Strategy: bioAffinity Technologies has prioritized CyPath® Lung as its core focus, driving growth through the expansion of ordering physician sites, enhanced peer-to-peer education among pulmonologists, and integration into clinical workflows, thereby improving lung cancer risk management.
- Future Expansion Plans: The company is advancing multiple initiatives to enhance the clinical impact of its proprietary technology platform, including a large-scale longitudinal clinical study and broader use of CyPath® Lung for monitoring lung cancer survivors, demonstrating its commitment to early cancer detection and market potential.
See More
bioAffinity Technologies Reports Q1 Financial Results
- Financial Performance: bioAffinity Technologies reported a Q1 GAAP EPS of -$0.81, indicating ongoing challenges in profitability and reflecting persistent financial pressure on the company.
- Revenue Decline: The company generated $1.35 million in revenue for the first quarter, a significant drop from $6.2 million in the same period last year, suggesting a potential weakening in market demand that could impact future growth prospects.
- Liquidity Concerns: As of March 31, 2026, cash and cash equivalents stood at $3.1 million, down from $6.4 million as of December 31, 2025, highlighting urgent issues in cash management and operational sustainability.
- Clinical Integration Efforts: bioAffinity Technologies is discussing the clinical integration of its CyPath lung product in pulmonary nodule assessment and early lung cancer diagnosis, which, despite poor financial results, may pave the way for future market opportunities.
See More
CyPath® Lung Diagnostic Sales Surge 146% Year-Over-Year
- Significant Sales Growth: In Q1 2026, CyPath® Lung diagnostic unit sales surged 146% year-over-year, reflecting rapid physician adoption and expanded clinical use, thereby enhancing the company's competitive edge in the non-invasive lung cancer detection market.
- Revenue Changes: CyPath® Lung testing revenue reached approximately $361,000, a 114% increase, while total revenue decreased by 27% to $1.4 million, primarily due to the discontinuation of unprofitable pathology services, allowing a focus on higher-margin CyPath® Lung testing.
- Clinical Trial Launch: The company initiated a large-scale longitudinal clinical trial, partially funded by the U.S. Department of Defense, expected to include up to 20 clinical sites, aimed at further validating CyPath® Lung's performance and establishing it as a standard of care in military and Veterans Administration medical centers.
- Strategic Investment and Market Expansion: bioAffinity Technologies plans to conduct a 40-patient collaborative study with Brooke Army Medical Center, utilizing its flow cytometry + AI technology to evaluate its platform's application in personalized therapy, further driving market acceptance of CyPath® Lung.
See More
BIOAFFINITY TECHNOLOGIES INC REPORTS 27% DROP IN TOTAL CONSOLIDATED REVENUE TO $1.4 MILLION FOR Q1 2026
- Revenue Decline: BioAffinity Technologies reported a 27% decrease in consolidated revenue, totaling $1.4 million in Q1 2026.
- Financial Performance: The significant drop in revenue indicates potential challenges for the company in maintaining financial stability and growth.
See More
